Polaryx Therapeutics, today announced that it has received from the U.S. Food and Drug Administration (FDA) both Rare Pediatric Disease and Orphan Drug Designations ... Dec 18
Polaryx Therapeutics has received from the US FDA both Rare Pediatric Disease and Orphan Drug designations for the treatment of GM2 gangliosidosis with PLX-300... Nov 25
-Advertisements-